Why Compounding Matters (and When It Does Not)

Most patients who receive compounded medications have only a vague sense of what compounding is, who is doing it, and how it differs from the manufacturing process behind FDA-approved pharmaceuticals. This is not a trivial gap. The compounding pharmacy that fills your prescription has substantial influence over what you actually receive — its identity, potency, sterility, and consistency. Understanding the compounding regulatory landscape helps you evaluate whether your care meets reasonable quality standards.

This article explains what compounding is, the difference between 503A pharmacies and 503B outsourcing facilities, when compounding quality matters most, and what to ask about the pharmacy filling your prescription.

What compounding actually is

Compounding is the process of preparing a medication for an individual patient based on a licensed prescriber’s prescription. The compounding pharmacy combines pharmaceutical ingredients (active ingredients and excipients) according to a specific formula to produce a finished medication ready for the patient.

This is fundamentally different from manufacturing. A pharmaceutical manufacturer produces large batches of finished products that are tested, packaged, and distributed broadly. A compounding pharmacy prepares individual or small-batch medications based on prescriptions for specific patients.

Compounding has a very long history in medicine. Before the rise of modern pharmaceutical manufacturing in the early 20th century, virtually all medications were compounded in pharmacies. Even today, compounding fills important clinical roles: preparing pediatric formulations of adult medications, creating dye-free or preservative-free versions for patients with sensitivities, and providing medications during commercial shortages.

One point is worth stating plainly: compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed. That is true whether the medication comes from a 503A pharmacy or a 503B outsourcing facility.

The two regulatory categories: 503A and 503B

The Drug Quality and Security Act of 2013 established two regulatory frameworks for compounding, named after sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

503A traditional compounding pharmacies prepare medications for individual patients on a prescription-by-prescription basis. They are regulated primarily by state pharmacy boards rather than the FDA. They cannot legally produce medications in advance of receiving prescriptions, and they cannot ship medications across state lines in large quantities. Their compounding standards are governed by USP (United States Pharmacopeia) chapters, particularly USP <795> for non-sterile compounding and USP <797> for sterile compounding.

503A pharmacies vary widely in size, sophistication, and quality. Some are small neighborhood pharmacies that compound a handful of prescriptions per week. Others are large specialty operations that compound thousands of complex prescriptions annually with sophisticated quality control. The regulatory minimum standards apply to all of them, but practice quality varies substantially.

503B outsourcing facilities are a newer category created to address gaps that became visible after the 2012 New England Compounding Center fungal meningitis outbreak. 503B facilities can produce sterile compounded medications in larger batches without individual prescriptions and can supply them to healthcare facilities for use in the office or clinic. They register with the FDA, follow current Good Manufacturing Practice (cGMP) requirements similar to those for pharmaceutical manufacturers, and are subject to routine FDA inspection.

503B compliance is substantially more demanding than 503A compliance. Facility design, environmental monitoring, equipment qualification, batch documentation, stability testing, and quality assurance systems are all held to higher standards. The trade-off is that 503B operations are larger, more expensive to run, and produce a narrower range of products than the 503A market. FDA registration and inspection of the facility does not make its products FDA-approved.

503A vs 503B at a glance

• Who regulates it: 503A — primarily state boards of pharmacy. 503B — registered with and inspected by the FDA, plus state licensure.
• Prescription required: 503A — yes, for each individual patient. 503B — can compound in advance, without patient-specific prescriptions, for supply to healthcare facilities.
• Quality standard: 503A — USP <795> and <797>. 503B — current Good Manufacturing Practice (cGMP).
• Typical use: 503A — patient-specific prescriptions dispensed to the patient. 503B — standardized sterile products used by clinics and hospitals.
• FDA-approved products? Neither. Compounded medications from either category are not FDA-approved.

Why sterile compounding matters

Many compounded medications are sterile injectable products. Sterile compounding is significantly more demanding than non-sterile compounding because contamination directly enters the bloodstream when the medication is injected. The 2012 fungal meningitis outbreak, which killed 64 people and sickened over 700, was caused by contaminated sterile injectable products from a compounding pharmacy that did not maintain adequate sterility controls.

For sterile injectable medications, the quality standards of the compounding pharmacy translate directly into patient safety. The pharmacy environment must maintain controlled air quality. Equipment must be regularly qualified and validated. Personnel must undergo specific training and aseptic technique testing. Batches should be subjected to sterility testing, endotoxin testing, and potency verification.

Pharmacies that perform these steps rigorously produce products that consistently meet specifications. Pharmacies that cut corners produce variable products with unpredictable risks. The patient typically cannot tell the difference from looking at the vial.

Compounding and FDA-approved drugs

When a drug is available as an FDA-approved commercial product (for example, the semaglutide products Ozempic, Wegovy, and Rybelsus), the general rule is that compounding essentially identical copies is restricted. Compounding pharmacies generally cannot produce copies of commercially available FDA-approved drugs. Exceptions exist for documented drug shortages, for patient-specific clinical needs that the commercial product cannot meet, and for certain other narrow circumstances.

The semaglutide and tirzepatide situation illustrates this. When these drugs were on the FDA Drug Shortage List, compounding pharmacies could legally prepare compounded semaglutide and tirzepatide to address the shortage — though, like all compounded drugs, these preparations were not FDA-approved. When the FDA declared the shortages resolved, the regulatory pathway for general semaglutide and tirzepatide compounding closed substantially. Some compounding remains legal under specific narrow circumstances, but broad compounding of these drugs has been the subject of FDA enforcement action.

This is important context for patients. A clinic offering a compounded medication should be able to explain the specific legal basis for it (an individualized formulation requirement, a documented clinical need, or another recognized basis). A clinic that cannot articulate this basis is operating in a gray zone that may close suddenly under enforcement action.

When compounding quality matters most

Compounding quality matters most for sterile injectable products, particularly those administered repeatedly over long courses of therapy. The cumulative exposure to subtle quality issues can produce problems that may not be immediately visible.

Compounding quality matters less for short-course oral products and topical products, where the contamination and sterility risks are lower and the consequences of variability are more limited.

What to ask about your compounding pharmacy

If your prescription is being filled by a compounding pharmacy, useful questions include:

What is the pharmacy’s regulatory category? A 503A pharmacy or a 503B outsourcing facility. Both can produce quality products; 503B facilities operate under higher minimum standards and FDA inspection.

Is the pharmacy licensed and in good standing? It should hold current state pharmacy licenses and have a clean inspection history with its state board of pharmacy. You can verify license status directly with the board.

Does the pharmacy follow USP chapters for sterile compounding? For sterile injectable products, the answer should be specifically “yes, USP <797>” (or cGMP for a 503B facility).

Does the pharmacy perform third-party testing? Reputable operations test for sterility, endotoxin, and potency and can provide certificates of analysis.

How does the pharmacy handle adverse event reporting? Quality operations have systems to track and address reported issues.

You should not need to ask all of these questions for every prescription, but knowing where your medications come from is reasonable due diligence — particularly if you are starting long-term therapy.

How The Tide handles compounding

When a compounded medication is appropriate, we send prescriptions to licensed pharmacies with documented quality systems, third-party testing, and clean regulatory histories. Patients may choose a different licensed pharmacy if they prefer.

For medications we administer in the clinic, we expect suppliers to provide certificates of analysis for the batches we receive, follow the quality standards that apply to their regulatory category, and maintain established adverse event reporting systems.

Bottom line

Compounding is a legitimate and important part of medical practice, but compounded medications are not FDA-approved, and the quality of the pharmacy substantially affects what you actually receive. The 503A and 503B frameworks — and the USP and cGMP standards within them — provide a way to evaluate that quality. Asking your prescriber and pharmacy the right questions is reasonable due diligence and should be welcomed by competent practices.

Compounding does not need to be intimidating, but it does deserve the same attention you would give to any aspect of your medical care. Knowing where your medications come from and how they are made is part of being an informed patient.